On the stock market since 2009, it operates in the world of health and science. It has 45,300 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The gap is $3.7B. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price looks reasonable next to what the company earns.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 28% below its peak. The market has trimmed its expectations for the company.
It pays out $0.25 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales fell about 5% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 23/100.
The growth engine is running at low revs right now. Report-card grade: 36/100.
On our five-subject report card, SEM sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SEM is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.